Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Public ClinicalTrials.gov record NCT00868608. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study Of Inotuzumab Ozogamicin (Cmc-544) In Subjects With Indolent Non-hodgkin's Lymphoma (Nhl) That Is Refractory To Or Has Relapsed After Rituximab And Chemotherapy Or Radioimmunotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or radioimmunotherapy. The investigational drug will be given to subjects with indolent NHL by intravenous infusion at a dose of 1.8 mg/m2, every 4 weeks.
Study identification
- NCT ID
- NCT00868608
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 81 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 30, 2009 (Actual)
- Primary completion
- Jan 10, 2012 (Actual)
- Completion
- Jun 27, 2013 (Actual)
- Last update posted
- Oct 31, 2017
2009 – 2013
United States locations
- U.S. sites
- 22
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35294-3300 | — |
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-3330 | — |
| University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35294 | — |
| Loma Linda University Cancer Center | Loma Linda | California | 92350 1700 | — |
| Loma Linda University Cancer Center #5 | Loma Linda | California | 92354 | — |
| Loma Linda University Medical Center | Loma Linda | California | 92354 | — |
| Facey Medical Group | Mission Hills | California | 91345 | — |
| Providence Holy Cross | Mission Hills | California | 91345 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Park Nicollet Frauenshuh Cancer Center | Saint Louis Park | Minnesota | 55426 | — |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| New York Medical College | Hawthorne | New York | 10532 | — |
| Quest Diagnostics | Allentown | Pennsylvania | 18103-6205 | — |
| Carlisle Regional Medical Center Lab | Carlisle | Pennsylvania | 17015 | — |
| Penn State Milton S. Hershey medical Center | Hershey | Pennsylvania | 17033-0850 | — |
| Lewistown Hospital | Lewistown | Pennsylvania | 17044 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | — |
| CMSA Medical Lab | State College | Pennsylvania | 16803 | — |
| University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00868608, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2017 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00868608 live on ClinicalTrials.gov.